Keyphrases
Cancer Therapy
100%
In Cancer
100%
Carcinoma
100%
Therapeutic Perspectives
100%
C-X-C Chemokine Receptor Type 4 (CXCR4)
100%
Chemokine Receptor CXCR4
100%
CXCR4 Antagonist
100%
HIV-associated
100%
Chemokine Receptor CCR5 Antagonists
100%
Clinical Trials
50%
Tumor
50%
Metastasis
50%
Immune Response
50%
Cancer Progression
50%
Tumor Progression
50%
Tumor Microenvironment
50%
Chemokine Ligand 12 (CXCL12)
50%
Malignant Cells
50%
New Alternatives
50%
Ligand-receptor Binding
50%
C-C Chemokine Receptor Type 5 (CCR5)
50%
Epithelial-mesenchymal Transition
50%
CCL5
50%
Combined Therapy
50%
Treatment Protocol
50%
Oncological Treatment
50%
Late Events
50%
CCR5 Antagonist
50%
Chemokine Ligands
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Receptor
100%
HIV
100%
Carcinoma
100%
Chemokine Receptor CCR5 Antagonist
100%
Chemokine Receptor CXCR4
100%
Chemokine Receptor CXCR4 Antagonist
100%
Neoplasm
50%
Tumor Growth
50%
Immunotherapy
50%
Chemokine
50%
Preclinical Study
50%
Cancer Growth
50%
Tumor Microenvironment
50%
Clinical Trial Results
50%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Cancer Therapy
100%
Carcinoma
100%
Chemokine Receptor CXCR4
100%
Chemokine Receptor CXCR4 Antagonist
100%
Chemokine Receptor CCR5 Antagonist
100%
Receptor
66%
Neoplasm
33%
Immune Response
33%
Chemokine
33%
Immunotherapy
33%
Tumor Progression
33%
Metastatic Carcinoma
33%
Tumor Microenvironment
33%
Cancer Growth
33%
Combined Therapy
33%
Clinical Trial Results
33%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
CXCR4
100%
CCR5
100%
Chemokine Receptor CXCR4
100%
Chemokine Receptor CCR5
100%
Chemokine
50%
Immunotherapy
50%
Immune Response
50%
Preclinical Study
50%
CCL5
50%